Dr. Mohane Coumar
About
Research Area
I have over 20 years of experience designing and synthesizing molecules for various drug discovery projects. Current emphasis on computer-aided drug design, cheminformatics, and Machine learning approaches for targeted anti-cancer therapy. My lab also focuses on anti-cancer target identification using omics data analysis.
I hold a Ph.D. in Pharmaceutical Sciences (Panjab University, Chandigarh) and have Post-doctoral research experience from Taiwan. Published over 100 research/review articles/book chapters; received over 2800 citations with an H-index of 30 (Scopus data). Co-inventor of 16 international patents (US8138194, US8507502, US9006252, EP 2331530, etc). Molecule designated as DBPR112 (Sponsor: National Health Research Institutes, Taiwan), one of my invention covered by the patents, is approved (IND 128699; April 8th, 2016) by US Food and Drug Administration for testing in humans for the treatment of Cancer; DBPR112 is undergoing Phase 1b/2 clinical trials in Taiwan for patients with advanced solid tumor and NSCLC with HER2 mutations (ClinicalTrials.gov Identifier: NCT03246854; NCT05532696). Edited a book on “Molecular Docking for Computer-Aided Drug Design” for Elsevier in 2021.
Notable & Recent Publications
Himanshu Tahiliani, Arunkumar Dhayalan, Mu-Chun Li, Hsing-Pang Hsieh, Mohane Selvaraj Coumar*. Aldehyde dehydrogenases as drug targets for cancer: SAR and structural biology aspects for inhibitor design. Bioorganic Chemistry, 2025, 154, 108019. [IF: 4.5].
Jie-Ning Li, Ming-Yang Wang, Jhen-Wei Ruan, Yu-Jhen Lyu, Yi-Hsiu Weng, Pownraj Brindangnanam, Mohane Selvaraj Coumar, Pai-Sheng Chen. A transcription-independent role for HIF-1α in modulating microprocessor assembly. Nucleic Acids Research, 2024, 11806–11821. JCR 2023 [IF: 16.7].
Mu-Chun Li, Mohane Selvaraj Coumar, Shu-Yu Lin, Yih-Shyan Lin, Guan-Lin Huang, Chun-Hwa Chen, Tzu-Wen Lien, Yi-Wen Wu, Yen-Ting Chen, Ching-Ping Chen, Yu-Chen Huang, Kai-Chia Yeh, Chen-Ming Yang, Bikashita Kalita, Shiow-Lin Pan, Tsu-An Hsu, Teng-Kuang Yeh, Chiung-Tong Chen, Hsing-Pang Hsieh. Development of furanopyrimidine-based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer. J Medicinal Chemistry 2023, 66 (4), 2566-2588 [IF: 6.9]
SK Kondapuram, HK Ramachandran, H Arya, MS Coumar*, Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development. Life Sciences, 2023, 122260. [IF: 5.2]
R. Vasundhara Devi, S. Siva Sathya, Mohane Selvaraj Coumar. Multi-objective biofilm algorithm (MOBifi) for de novo drug design with a special focus to anti-diabetic drugs. Applied Soft Computing. 2020, 96, 106655 [IF: 7.2].
